Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Featured products

Featured products

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
A482 Setoxaximab Biosimilar(Anti-Shiga toxin (E.coli) Reference Antibody) Featured
Setoxaximab is an IgG1-κ humanized chimeric antibody targeting shiga toxin type 1.
More description
A481 Pritoxaximab Biosimilar(Anti-Shiga toxin (E.coli) Reference Antibody ) Featured
Pritoxaximab is an IgG1κ antibody targeting shiga toxin type 1.
More description
DC60799 TDI-015051 Featured
TDI-015051 is a first-in-class non-covalent inhibitor of the viral guanine-N7 methyltransferase (MTase) NSP14 with Kd of 61 pM and IC50 ≤ 0.15  nM, respectively.
More description
DCD-041 Cholesterol Featured
Cholesterol is a component of Lipid nanoparticles (LNPs) for RNA delivery.
More description
DC10988 LTX-401 Featured
LTX-401 is a novel oncolytic amino acid derivative that specifically targets the Golgi apparatus, demonstrating significant potential in cancer therapy. In vitro studies reveal that LTX-401 effectively reduces the viability of various tumor cell lines, exhibiting cytotoxic activity across a range of concentrations. Notably, it shows the highest potency against the human malignant melanoma cell line MDA-MB-435S (IC50 = 13.5 μM) and the lowest activity against the human hepatocellular carcinoma cell line HEPG2 (IC50 = 35.4 μM). For other cell lines, the IC50 values fall within a narrow range of 19-32 μM. Importantly, LTX-401 does not induce hemolysis in red blood cells at concentrations effective for cancer cell death, with hemolytic activity only observed at much higher concentrations (400 μg/mL = 1087 μM). Additionally, LTX-401 demonstrates cytotoxicity against non-malignant cell lines, including HUV-EC-C endothelial cells, HaCat keratinocytes, and MRC-5 fibroblasts, suggesting a broad but selective mechanism of action.
More description
DCC0219 3-brop Featured
Prodrug of the glycolysis inhibitor 3-bromopyruvate (3-BrPA) which targets hexokinase II (HK2) and GAPDH
More description
DC8914 Indacaterol Featured
Indacaterol is a potent, orally administered ultra-long-acting β2 adrenergic receptor (ADRB2) agonist, widely recognized for its therapeutic potential in respiratory and cardiovascular conditions. By selectively activating ADRB2, indacaterol not only enhances bronchodilation but also exhibits a unique mechanism of action by inhibiting NF-κB activity in a β-arrestin2-dependent manner. This dual functionality helps mitigate lung inflammation, prevent further pulmonary damage, and improve lung function in patients with chronic obstructive pulmonary disease (COPD). Beyond its respiratory applications, indacaterol has also emerged as a valuable tool in cardiovascular disease research, offering insights into its broader therapeutic effects. Its multifaceted pharmacological profile positions indacaterol as a promising candidate for addressing complex disease mechanisms and advancing treatment strategies in both respiratory and cardiovascular fields.
More description
DC41699 FSLLRY-NH2 Featured
FSLLRY-NH2 is a protease-activated receptor 2 (PAR2) inhibitor.
More description
DC10762 Edonerpic maleate Featured
Edonerpic, also known as T-817, is a neuroprotectant. Edonerpic is a candidate therapeutic agent for Alzheimer's disease that inhibits oxidative stress and nitric oxide-induced neurotoxicity and acts as a neurotrophic factor. Edonerpic protects against MPTP-induced neurotoxicity by blocking lipid peroxidation in the SNc, and imply that this compound may be useful for treating neurodegenerative disorders related to oxidative stress, such as Parkinson's disease.
More description
DC50040 GNF-PF-3777 (8-Nitrotryptanthrin) Featured
GNF-PF-3777 (8-Nitrotryptanthrin) is a potent human indoleamine 2,3-dioxygenase 2 (hIDO2) inhibitor which significantly reduces IDO2 activity with Ki of 0.97 μM.
More description
DC67211 m7GpppAmpG Na salt Featured
m7GpppAmpG Na salt is a trinucleotide 5′ cap analog with the capping efficiencies for the obtained RNAs of 90%.
More description
DC67197 m7GpppAmpG ammonium Featured
m7GpppAmpG ammonium is a trinucleotide 5′ cap analog with the capping efficiencies for the obtained RNAs of 90%.
More description
DC67221 3'OMe-m7GpppAmpG (ammonium) solution (100mM) Featured
3'OMe-m7GpppAmpG ammonium solution (100mM) is a trinucleotide Cap analogue. 3'OMe-m7GpppAmpG ammonium shows a significant translational efficiency. 3'OMe-m7GpppAmpG ammonium can be used as a potential molecular biology tool in the field of mRNA vaccines and mRNA transfection, such as protein production, gene therapy and anti-cancer immunization.
More description
DC49193 PEG2000-C-DMG Featured
PEG(2000)-C-DMG represents a PEGylated derivative synthesized from 1,2-dimyristoyl-sn-glycerol (1,2-DMG). This compound is instrumental in the formulation of lipid nanoparticles (LNPs), particularly when combined with other lipidic compounds, for the efficient delivery of small interfering RNA (siRNA). Specifically, LNPs incorporating PEG(2000)-C-DMG and encapsulating siRNA designed to target the genes responsible for encoding programmed cell death protein ligand 1 (PD-L1) and PD-L2 have demonstrated efficacy in reducing the expression levels of PD-L1 and PD-L2 in monocyte-derived dendritic cells. Furthermore, formulations that include PEG(2000)-C-DMG are being actively explored in the advancement of LNPs aimed at the delivery of siRNA-based vaccines, highlighting its critical role in the development of therapeutic and prophylactic strategies.
More description
DC47310 Rovanersen Featured
Rovanersen (WVE-120101) is an antisense oligonucleotide that can be used for huntington’s disease research.
More description
DC67161 MPEG-2000-DPPE Na Featured
DPPE-MPEG(2000) is a PEGylated form of 1,2-dipalmitoyl-rac-glycero-3-PE (DPPE). It has been used in the synthesis of anionic liposomes for drug redistribution and toxicity prevention.
More description
DC13591 azido-acetal linker(Acid-degradable liker) Featured
Azido-acetal linker is stable at physiological pH (7.4) but rapidly hydrolyzes in the acidic environment of endosomes useful as a fragment of lipid synthesis.
More description
DC67312 1-Propanethiol, 3-(diMethylaMino)-, hydrochloride Featured
DC67311 1-Propanaminium, 2,3-dihydroxy-N,N,N-trimethyl-, chloride (1:1), (2R)- Featured
DC67310 1,4-Piperazinediethylamine Featured
DC67309 H2N(CH2)3N(tert-butoxycarbonyl)(CH2)4NH2 Featured
DC65568 C14-494 Core (Lipid Core 494) Featured
C14-4 Core (Core 4) is the core structure of C14-4.
More description
DC67308 CbzNH-PEG1-Br Featured
DC67307 1-Piperazineethanamine, N-(phenylmethyl)- Featured
DC11375 KRIBB3 Featured
KRIBB3 is an Hsp27 and microtubule inhibitor that inhibits migration and invasion of MDA-MB-231 cells in vitro in an Hsp27-dependent manner.
More description
DC22085 Tasurgratinib(E7090) Featured
E7090 (E 7090) is a highly potent and selective orally bioavailable inhibitor targeting FGFR1, FGFR2, and FGFR3, with IC50 values of 0.71 nM, 0.50 nM, and 1.2 nM, respectively. It exhibits significantly weaker inhibition of FGFR4, with an IC50 of 120 nM. This distinct selectivity profile positions E7090 as a promising therapeutic candidate for diseases driven by aberrant FGFR1-3 signaling, offering a targeted approach to inhibit these receptors while minimizing off-target effects on FGFR4. Its oral availability further enhances its potential as a convenient and effective treatment option for patients with FGFR-dependent conditions.
More description
DC67305 BMS-1166-N-piperidine-COOH Featured
BMS-1166-N-piperidine-COOH, a derivative of the potent PD-1/PD-L1 interaction inhibitor BMS-1166, serves as a key component in the design of PROTAC PD-1/PD-L1 degrader-1 (HY-131183). By binding to an E3 ligase ligand via a linker, this moiety facilitates the targeted degradation of PD-1/PD-L1, offering a novel approach to modulate immune checkpoint pathways. BMS-1166 itself is a highly effective inhibitor of the PD-1/PD-L1 interaction, with an IC50 of 1.4 nM, and it counteracts the immune-suppressive effects of the PD-1/PD-L1 checkpoint on T cell activation. This innovative strategy combines the inhibitory potency of BMS-1166 with the degradation capability of PROTAC technology, providing a promising tool for advancing cancer immunotherapy and immune-related research.
More description
DC67304 JMV6944 Featured
JMV6944 is a potent agonist of the pregnane X receptor (PXR), demonstrating its ability to competitively inhibit the binding of the human PXR ligand-binding domain (LBD) with an IC50 value of 680 nM. This compound effectively induces the expression of CYP3A4 mRNA in freshly isolated primary human hepatocyte cultures, highlighting its role in modulating drug metabolism and detoxification pathways. JMV6944 serves as a valuable tool for investigating PXR-mediated transcriptional regulation and its implications in xenobiotic metabolism, liver function, and therapeutic interventions. Its dual functionality as a PXR agonist and CYP3A4 inducer underscores its potential in both research and drug development.
More description
DC8101 BS-181 hydrochloride Featured
BS-181 is a highly selective inhibitor of CDK7, exhibiting potent activity with an IC50 value of 21 nM. It demonstrates remarkable specificity, showing over 40-fold greater selectivity for CDK7 compared to other cyclin-dependent kinases, including CDK1, CDK2, CDK4, CDK5, CDK6, and CDK9. This exceptional selectivity positions BS-181 as a valuable tool for studying CDK7-specific biological functions and exploring its therapeutic potential in diseases where CDK7 plays a critical role, such as cancer. Its precision in targeting CDK7 underscores its utility in both research and drug development efforts.
More description
DC67303 I-152 Featured
I-152 is a novel conjugate composed of N-acetyl-cysteine (NAC) and cysteamine (MEA), designed to harness the synergistic effects of these two bioactive compounds. It demonstrates the ability to activate key cellular signaling pathways, including NRF2 and ATF4, which are involved in oxidative stress response and cellular homeostasis. Additionally, I-152 exhibits potent anti-proliferative properties, making it a promising candidate for research in conditions characterized by uncontrolled cell growth, such as cancer. This unique combination of NAC and MEA in I-152 offers a multifaceted approach to modulating cellular pathways and addressing pathological processes.
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X